Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-07-24
2000-02-01
Campell, Bruce R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
4353201, 424 932, A61K 4800, A61K 3500, C12N 1563
Patent
active
060203196
ABSTRACT:
Method for DNA-based immunotherapy of mammalian subjects in the treatment of chronic hepatitis B infection through a series of injections of DNA transcription units encoding hepatitis B surface antigen followed by booster injections of a DNA transcription unit encoding at hepatitis B surface antigen.
REFERENCES:
patent: 5643578 (1997-07-01), Robinson et al.
Davis et al. DNA-mediated immunization to hepatitis B surface antigen: longevity of primary response and effect of boost. Vaccine, vol. 14, No. 9, pp. 910-915, Jun. 1996.
Davis, H. L. DNA-based vaccination against hepatitis B virus. Advanced Drug Delivery Reviews, vol. 21, pp. 33-47, Aug. 12, 1996.
Rabinovich et al. Vaccine Technologies: View to the Future. Science, vol. 265, pp. 1401-1404, Sep. 2, 1994.
Whalen et al. DNA-Mediated Immunization and the Energetic Immune Response to Hepatitis B Surface Antigen. Clinical Immunology and Immunotpathology, vol. 75, No. 1, pp. 1-12, 1995.
Akbar, S. M. Fazle, et al., "Placebo-controlled trial of vaccination with hepatitis B virus surface antigen in hepatitis B virus transgenic mice," Journal of Hepatology, vol. 26, pp. 131-137 (1997).
Ma, Z.M., et al., "Recombinant Vaccinia Virus Expressing Pre-S/S Protein of Duck Hepatitis B Virus and its Preliminary Use for Treatment of Persistent Infection," Acta Virologica, vol. 40, pp. 311-314 (1996).
Mancini, M., et al., "DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state," Proc. Natl. Acad. Sci. USA, vol. 93, pp. 12496-12501 (Oct. 1996).
Pol, Stanislas, et al., "Efficacite d'une immunotherapie par vaccination contre le virus de l'hepatite B sur la multiplication virale B," C. R. Acad. Sci. Paris., Sciences de la vie, vol. 316, pp. 688-691 (1993).
Pol, Stanislas, et al., "Specific vaccine therapy in chronic hepatitis B infection ," The Lancet, vol. 344, p. 342 (Jul. 30, 1994).
Tartaglia, James, et al., "NYVAC: A Highly Attenuated Strain of Vaccinia Virus," Virology, vol. 188, pp. 217-232 (1992).
Brotman Betsy
Prince Alfred M.
Campell Bruce R.
Clark Deborah J. R.
Lenna Leo G.
New York Blood Center
Steifel Maurice B.
LandOfFree
Nucleic acid based immunotherapy of chronic hepatitis B infectio does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acid based immunotherapy of chronic hepatitis B infectio, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid based immunotherapy of chronic hepatitis B infectio will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-937618